Pharmaceuticals, Biotechnology and Life Sciences
CHANDLER, Ariz.–(BUSINESS WIRE)–#AZBW–The Arizona Bioindustry Association (AZBio) today announced that Regenesis Biomedical, Inc. has been named the Arizona Bioscience Company…
Dr. Geall Joins the Company’s World-class Scientific Advisors in Cardiology, Vaccine Development and Human Genetics CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a…
MIDLAND PARK, N.J.–(BUSINESS WIRE)–Medality Medical LLC (“Medality” or the “Company”), a U.S.-based medical technology company, announced that it has received…
Top Korean food and biotech manufacturer reinforces commitment to increasing efficiency of more sustainable, scalable and cost-effective biotechnology production solutions…
– Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 – BOTHELL, Wash. &…
– Final Data Readout of Pilot Trial Evaluating SkinTE for Treatment of Venous Stasis Leg Ulcers Designated Highest Scoring Poster…
Believes Removal of Four Incumbent Directors is Necessary to Stop Value Destruction at AMAG Caligan’s Four Highly-Qualified Nominees Have the…
-Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Lansoprazole Delayed-Release Capsules USP, 15 mg, an over-the-counter (OTC) store-brand equivalent of Prevacid® 24HR Capsules, in the United States market, as approved by the U.S. Food and Drug Administration (USFDA).
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Allergenic Products Advisory Committee (APAC) convened by the U.S. Food and Drug Administration (FDA) voted to support the use of AR101 (proposed trade name PALFORZIA™) in children and teens with peanut allergy.
Technavio’s market research reports examine the competitive landscape and provide detailed insights into the market scenario over the next five years.